Gilead Revenue Soars on Hepatitis C Drug - The New York Times
Gilead says counterfeiters sold $250M worth of fake HIV drugs, sues distributors | Fierce Pharma
Gilead to donate HIV prevention drug Truvada to 200K uninsured patients
United States v. Gilead: The Fight for PrEP | Bill of Health
Top Research Reports for JPMorgan, Gilead Sciences & CSX
AHF • AHF Calls on Gilead to Set Up $10 Billion Fund for Victims Harmed by its TDF-based Drugs
Gilead Will Donate Truvada to U.S. for H.I.V. Prevention - The New York Times
Untangling the Trump administration's lawsuit over an HIV prevention drug | Science | AAAS
Gilead drug shows positive signs in early coronavirus testing | Financial Times
Gilead's (GILD) Sunlenca Wins FDA Approval for HIV Resistant to Other Drugs - Bloomberg
PrEP's Still Too Costly For Many People At Risk For HIV : Shots - Health News : NPR
NYC DOHMH Advisory about Tampered and/or Counterfeit Versions of Biktarvy and Descovy - GMHC
Gilead Advancing Access®: What to Know | Prism Health North Texas
Gilead prices remdesivir at $2,340 per patient for developed countries
U.K. marketing police slam Gilead for claiming Biktarvy tolerability beats GSK rival | Fierce Pharma
Gilead to launch generic versions of hepatitis C drugs | Modern Healthcare
Single patient study adds to debate over Gilead's remdesivir for COVID-19 | Reuters
Xaiver University of Louisiana's College of Pharmacy is collaborating with Gilead Sciences and Morehouse School of Medicine to address health inequities - Xavier University of Louisiana
Study: To be cost-effective, Gilead's new HIV pill needs near-50% price cut
Sovaldi: Who's to Blame for the $1,000 a Day Cure? - Knowledge at Wharton
Generic HIV prevention drug coming in 2020, Gilead says
Gilead reaches multiyear agreement with White House to donate PrEP
Appeal lodged against decision to uphold Gilead's patent on hepatitis C drug | MSF
How an $84,000 drug got its price: 'Let's hold our position … whatever the headlines' - The Washington Post
